Name
Address
E-mail
Publication title
Publication journal
Phase of clinical trial
Phase_I
Phase_II
Phase_III
Type of CIK cells
Autologous cells
Allogenic cells
Tumor entity (diagnosis)
Number of patients
Number of males
Number of females
Median age
Age range
Stage of disease
Inclusion criteria
Exclusion criteria
Total number of CIK cells
HLA type of patients / CIK cells
Storage of CIK cells
Frozen
Fresh
Number of CIK cell infusions
CIK cell number per infusion
Hematologic toxicity
Non-hematologic toxicity
Time period of follow-up
Duration of responses
Immunologic responses
Median follow-up in months
Comments
Send